1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
National Cancer Institute (NCI) SBIR/STTR Grants is a grant from the National Cancer Institute (NCI) of NIH that funds small businesses developing innovative cancer-related technologies and treatments. The program supports both SBIR (company-led) and STTR (research institution partnership) projects through investigator-initiated grants and NCI-defined contracts.
Phase I grants are approximately $300,000 and Phase II awards exceed $2 million. Grant submissions are accepted three times per year; contracts are accepted once annually and focus on NCI priority areas. Eligible applicants are small businesses meeting NIH SBIR/STTR requirements proposing projects within NIH's research mission.
Note: NIH SBIR/STTR legislative authority expired October 1, 2025; check NCI's site for current status.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI) of NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Funding - NCI NIH has no active Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) solicitations because the legislative authority for the programs expired on October 1, 2025. Current recipients should direct any questions to their Program Officer. See NOT-OD-26-006 .
NCI SBIR/STTR Small Business Funding Researcher-initiated projects that are within the National Institutes of Health’s (NIH) mission can receive small business funding, resources, and support from the NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Funding is primarily awarded through either a grant or a contract, though supplemental awards are also available.
Grants are investigator-initiated, whereas contracts are defined by NIH. Grant submissions are accepted three times per year, except for targeted solicitations, which have variable receipt dates. Contract submissions are accepted only once per year and focus on NCI priority areas.
Contracts are awarded to projects that have a strong potential for commercial success, and development progresses with significant oversight from NCI. The NCI SBIR Contract funding is a unique funding opportunity that involved NCI-defined requirements, deliverables, and schedule.
NCI SBIR/STTR Supplement Awards Small Business Application Process and Resources Application resources are available to small businesses so they can apply for Phase I SBIR/STTR funding.
According to the current listing, eligibility includes: Most grant requirements allow applications with an investigator-defined scope within the mission of NIH. Small businesses must meet general NIH SBIR/STTR eligibility requirements. Confirm the full requirements in the official notice before applying.
The current listing shows varies by phase (e.g., ~$300k for Phase I, ~$2M+ for Phase II). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for National Cancer Institute (NCI) SBIR/STTR Grants are due September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
National Cancer Institute (NCI) SBIR/STTR Grants is funded by National Cancer Institute (NCI) of NIH. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read articleNew NIH awards have fallen 34% in 2026, NSF is running months behind, and a proposed OMB rule would let political appointees terminate grants mid-stream. The funding environment for academic research has structurally changed. Here is a clear-eyed diversification strategy for PIs, research offices, and institutions that cannot wait for the political fight to resolve.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read article